Attention-deficit hyperactivity disorder is referred to as attention deficit disorder when impulsivity or hyperactivity is not present. Attention-deficit hyperactivity disorder is mostly diagnosed in childhood and often persists till adulthood. It is a chronic condition where treatment cannot cure the patient; however, early diagnosis and treatment of the disease could mitigate the symptoms.

The global attention-deficit/hyperactivity disorder (ADHD) therapeutics market is estimated to account for US$ 19,293.6 Mn in terms of value and is expected to reach US$ 29,996.9 Mn by the end of 2027.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Drivers

Increasing clinical trials in attention-deficit hyperactivity disorder is expected to propel growth of the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market over the forecast period. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a U.S. subsidiary, announced positive top-line results from phase 3 clinical trials that evaluated the efficacy, safety and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention-deficit hyperactivity disorder.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Opportunities

R&D in substance use patterns among young adults with attention-deficit/hyperactivity disorder is expected to offer lucrative growth opportunities for players in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market. For instance, in May 2020, a team of researchers from PISA-School of Experimental and Clinical Psychiatry, Italy, and University of Pisa, Italy, reported that the presence of different comorbid substance use disorders clusters do not affect attention-deficit/hyperactivity disorder-specific symptomatology or severity at treatment entry.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Restraints

Contraindications and side-effects associated with attention-deficit/hyperactivity disorder drugs are also expected to hinder growth of the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market. Contraindications such as allergic reaction to a molecule or any other medicine, medical condition such as coronary artery disease, bipolar disorder, blood vessel problems, hypertension, kidney disease, seizures, pancytopenia, mydriasis, thrombocytopenic purpura, visual disturbances are associated with hinder growth of the attention-deficit/hyperactivity disorder drugs.

Key Takeaways:

The global attention-deficit/hyperactivity disorder (ADHD) therapeutics market was valued at US$ 18,133.1 Mn in 2019 and is forecast to reach a value of US$ 29,996.9 Mn by 2027 at a CAGR of 6.5% between 2020 and 2027. Major factor driving the growth of global attention-deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period include increasing prevalence of attention-deficit/hyperactivity disorder, and increasing research and development.

Stimulants held dominant position in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market in 2019, accounting for 86.1% share in terms of value, followed by non-stimulants, respectively. Product launches in the stimulant segment is supporting growth of the segment.

Market Trends

Major players in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market are focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in January 2019, Otsuka America, Inc. collaborated with Click Therapeutics, Inc. to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder.

Major players in the market are also focused on adopting various marketing strategies to enhance their market share. For instance, in December 2018, RespireRx Pharmaceuticals Inc. attended the International Cannabinoid Derived Pharmaceuticals Summit in the U.S.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Competitive Landscape   

Major players operating in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market include, Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Key Developments

October 2018: Otsuka Pharmaceutical Co., Ltd. collaborated with Proteus Digital Health for the further development and commercialization of a portfolio of medicines including the ABILIFY MYCITE (aripiprazole tablets with sensor) offering, which received NDA approval from the U.S. Food and Drug Administration in November 2017.

Segmentation

  • By Drug Type
    • Stimulants
      • Amphetamine
      • Methylphenidate
      • Dextroamphetamine
      • Dexmethylphenidate
      • Lisdexamfetamine Dimesylate
    • Non-stimulants
      • Atomoxetine
      • Bupropion
      • Guanfacine
      • Clonidine
  • By Age Group
    • Pediatric and Adolescent
    • Adults
  • By Distribution Channel
    • Specialty Clinics
    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner